Premium
A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients
Author(s) -
Muijen M.,
Roy D.,
Silverstone T.,
Mehmet A.,
Christie M.
Publication year - 1988
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1988.tb06353.x
Subject(s) - mianserin , fluoxetine , placebo , psychology , nausea , reuptake inhibitor , anesthesia , vomiting , psychiatry , medicine , antidepressant , serotonin , anxiety , receptor , alternative medicine , pathology
Fluoxetine, a selective serotonin reuptake inhibitor, was compared with mianserin and placebo in a double‐blind study. In total, 81 depressed patients were included. Patients were rated weekly on the Hamilton Depression Rating Scale (HDRS) and the Montgomery & Asberg Depression Rating Scale (MADRS). The duration was 6 weeks, and 52 patients completed the study. Significantly more patients on fluoxetine improved than patients on placebo. For mianserin no significant differences were found with either fluoxetine or placebo. Mean HDRS at the end of the study was also statistically significantly lower for fluoxetine, but not for mianserin, than placebo. Subscores of the MADRS showed improved sleep on mianserin at weeks 2 and 3. Suicidal feelings were reduced to a greater degree on fluoxetine than on mianserin and placebo at weeks 6 and 7. Fluoxetine induced weight loss, while patients on mianserin gained weight. Side effects were present in most patients on the two active drugs; those on fluoxetine experienced nausea and vomiting, and those on mianserin drowsiness.